The HRH1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which the HRH1 gene has been disrupted to create a loss-of-function model for histamine H1 receptor studies. This heterogeneous population of edited alleles avoids clonal artifacts and enables robust phenotypic assessment, making it particularly suitable for pooled screening and population-level analyses. The product eliminates functional HRH1 protein via CRISPR/Cas9-mediated gene disruption, offering a versatile tool for dissecting histamine-dependent pathways in a lung cancer background.
The host cell line, NCI-H1299, is a well-characterized human non-small cell lung carcinoma model originally derived from a lymph node metastasis of a patient with lung adenocarcinoma. This adherent epithelial line is widely employed to investigate lung adenocarcinoma biology, including oncogenic signaling, metastasis, and therapeutic responses. Notably, NCI-H1299 lacks functional p53, facilitating studies of p53-independent mechanisms and serving as a relevant platform for cancer drug screening.
HRH1 encodes the histamine H1 receptor, a G??q-coupled GPCR that mediates pro-inflammatory and allergic actions of histamine. Upon histamine binding, HRH1 activates GNAQ and GNA11, leading to PLC??-mediated generation of IP3 and DAG. IP3 triggers calcium release via IP3 receptors, while DAG activates PKC. This signaling cascade drives NF-??B-dependent transcription of cytokines such as IL-6, IL-8, and TNF-alpha. Regulatory inputs include substance P, bradykinin, and PKC-mediated feedback, while ARRB1, ARRB2, and calmodulin modulate receptor desensitization. HRH1 knockout thus abolishes histamine-induced calcium mobilization and NF-??B activation, profoundly attenuating inflammatory mediator production.
In the NCI-H1299 lung adenocarcinoma context, HRH1 knockout enables dissection of histamine-driven inflammatory signaling in cancer. This model allows assessment of HRH1??s role in proliferation, migration, and cytokine secretion, key processes in tumor progression and immune microenvironment modulation. Moreover, defective HRH1 signaling can be linked to reduced inflammatory mediator release, providing a platform to investigate tumor-extrinsic effects of histamine within the tumor microenvironment and potential crosstalk with oncogenic drivers such as EGFR or KRAS.
Applications include western blotting and RT-qPCR for downstream targets (NF-??B, IL-6, IL-8), calcium flux assays, NF-??B reporter assays, and cell proliferation and migration studies. This product supports research into allergic diseases including allergic rhinitis, asthma, atopic dermatitis, urticaria, and anaphylaxis, as well as lung cancer biology. For further information or to discuss customized gene-editing solutions, please contact Ascent Research.
